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Cardiovascular diseases are the leading cause of mortality in hemodialysis patients. Patients are exposed 
to a number of risk factors for cardiovascular complications, which are the result of uremia and dialysis. Aim 
of our study was to examine the incidence of secondary hyperparathyroidism and left ventricular hypertro-
phy, the interplay between them as predictors of mortality. This prospective study included 53 patients. All 
patients had measured echocardiographic parameters of left ventricular hypertrophy and laboratory param-
eters of bone metabolism. We followed the death rate of patients over two years. Elevated levels of PTH 
in the serum was present in 79.24% of patients, hypertrophy of the left chamber was recorded in 81.13% 
of patients. The survivors had lower values  of PTH and phosphate levels which were significantly lower (p 
<0.05) in relation to deceased patients. Patients with poor outcome had higher LV mass index, lower EF and 
FSLV, larger diameters of interventricular septum and posterior wall (P <0.05). Left ventricular hypertrophy 
is premature cardiovascular disorder that develops rapidly during the progression of CKD and is based of 
uremic cardiomyopathy. Left ventricular hypertrophy is a strong indicator of mortality in patients with ESRD.
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Patients with the end-stage renal disease (ESRD) have 
a high mortality rate(1,2) that far exceeds the mortality 
rate for the non-ESRD population(3). Cardiovascular 
diseases are the leading cause of death in patients on 
hemodialysis (HD). The annual mortality rate from 
cardiovascular disease (CVD) in these patients is 9%. 
Cardiovascular system in HD patients is affected by 
a number of well-known risk factors (RF) dependent 
of uremia and dialysis. All these RF predisposing to 
atherosclerosis, which underlies CVD(4).
The high risk of cardiovascular morbidity and mortality 
in ESRD patients is associated with a high prevalence 
of classic cardiovascular RF (hypertension,diabetes 
mellitus, dyslipidemia, smoking, and advancedage). 
In addition, several uremia-related factors may also 
play an important role, namely, the presence of mul-
tiple comorbid conditions, fluid overload, secondary 
hiperparatireoidism (SHPT), hyperphosphoremia, high 
calcium-phosphorous product, anemia, left ventricular 
hypertrophy (LVH), inflammation, oxidative stress, 
endothelial dysfunction, insulin resistance, hyperho-
mocysteinemia, high levels of lipoprotein(a) and in-
creased asymmetrical dimethylarginine(5-8).
Disruption of calcium and phosphate metabolism occurs 
when the level of glomerular filtration rate (GFR) falls 
below 60 ml/min. With the decline of GFR is reduced 
formation of the active metabolite of vitamin D (calci-
triol). This results in decreased reabsorption of calcium 
from the gastrointestinal tract, and an increased secre-
tion of the parathyroid hormone (PTH). Increased phos-
phate concentration in the serum stimulates the parath-
yroid gland to produce and secrete increased PTH and 
this has resulted in the development of SHPT(9,10). SHPT 
contributes to the development of vascular and valvular 
calcification and cardiovascular complications. Calcifi-
cation of the arteries can affect intimacy and/or medium 
arterial walls of blood vessels and is associated with an 
increased deposit of calcium in atherosclerotic plaques, 
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increase in arterial stiffness, the development of ischemic 
heart disease and concentric LVH(11). Elevated phosphate 
levels is important in triggering artery calcification of 
media(12,13). Clinical trial results indicate a correlation 
between hyperphosphatemia, increased product solubil-
ity and left ventricular mass index (LVMi). Patients on 
HD are at higher risk for sudden cardiac death(14).
The aim of this study was to determine the prevalence 
of left ventricular hypertrophy, dilatation and systolic 
disfunction,  prevalence of SHPT and the impact of 
SHPT on left ventricular remodeling and cardiovas-
cular morbidity. Furthermore, we aimed to determine 
other cardiovascular mortality predictors  in patients on 
regular HD.
METHODS
The study included 53 patients (25 men and 28 wom-
en) treated with regular HD three times a week for four 
hours in Haemodialysis center/Nephrology department 
od Clinical center of Montenegro. Investigation included 
hemodynamically stable patients with different primary 
kidney disease. Patients were followed prospectivelly for 
two years.
During the examination analyzed parameters were: gen-
der and age structure of patients, PTH and bone-mineral 
metabolism, homocysteine(Hcy), high-sensitive C-reac-
tive protein (hsCRP), nutritional (albumins) and dialysis 
parameters (KT/V), serum lipid levels, natriuretic brain 
peptid(BNP), level of anemia and anthropometric param-
eters. We analyzed the echocardiographic parameters of 
the left ventricle:  LVMi (g/m²), end-diastolic left ven-
tricular volume index-iEDVLV, posterior wall (PWLVd) 
and interventricular septum diameter (IVSd) of left ven-
tricule, ejection fraction of left ventricule- LVEF and left 
ventricular fractional shortening- FSLV. PTH (11-67 pg/
ml) was determined from serum on automated system 
IMMuLITE 2000, chemiluminescent immunoassay. 
Calcium (Ca 2.15-2.55 mmol/l, Schwarzenbach meth-
od), phosphate (Phos 0.74-1.52 mmol/l, phosphometric 
metod), Alkaline phosphatase (AlkP 40-129 u/l men, 
35-104 u/l women, colorimetric method), Albumin (Alb 
35.6-46.1 g/l, immunoturbidimetric test),  cholesterol 
(CHOL, 3.80-5.17 mmol/l), triglycerides (TRIG, 0.00-
1.69 mmol/l), low density lipoproteins (LDL, 0.00-3.90 
mmol/l) and high density lipoproteins (HDL, 0.9-1.45 
mmol/l) were performed from the serum of the appli-
ance Roche Integra 400. Lipidogram was determined us-
ing enzymatic colorimetric test. Blood parameters were 
performed on the hematology analyzer Cell-Dyn 3700 
(Abbott). NTproBNP was performed from serum on au-
tomated system IMMuLITE 2000, chemiluminescent 
immunometric assay (ref. values  0.0-53.1 pmol/l). 
Echocardiography was performed on the appliance Phil-
lips, the probe of 2.5 MgHz transthoracic approach. 
LVH was determined by measuring LVMi:
LVMi = (0.00083x ((+ EDDLK IVSd ZZLKd +) - 
(EDDLK) 2) +0.6) / TP g/m2
The volume of left ventricle is calculated by the follow-
ing formula:
iEDVLV = ((EDDLK) x0.001047 3)/TP ml/m2
LVEF is calculated on the basis of the following formula:
LVEF(%) = (EDVLV-ESVLV) / EDVLV x 100%
(ESVLV - end-systolic left ventricular volume, EDVLV 
- end-dyastolic left ventricular volume, EDVLV- end-
dyastolic ventricular volume)
Left ventricular fractional shortening (FSLV) is calcu-
lated on the basis of the following formula:
FSLV = (EDDLK-ESDLK) / EDDLK x 100%
Normal values of echocardiographic parameters were: 
LVMi is ≤ 131 g/m2 for men and ≤100 g/m2 in women, 
iEDVLV is ≤90 mL/m2, LVEF 67 ± 9% and FSLV 42 ± 
8%. Systolic dysfunction is defined as a FSLV ≤25% and 
LVEF ≤50%. LVH is defined as the thickness of IVSd 
>11 mm, PWLVd  >11 mm, LVMi >131 g/m2 in men >100 
g/m2 in women. Left ventricular dilatation is defined as 
the inner diameter of the LV end-diastolic >57 mm, and 
LV volume >90 mL/m2, with normal systolic function 
and normal left ventricular mass index. Adequacy of di-
alysis was evaluated based on  Kt/Vsp calculated accord-
ing to following formula
Kt / Vsp = -ln (C2 / C1-0.008 x T) + (4-3.5xC2 / C1) x UF / W
where: C1 - predialysis urea value, C2 - postdialisys 
value of urea(mmol/L), T – duration hemodialysis (h), 
uF - between dialysis yield (l), W - body weight after 
hemodialysis (kg).
For the statistical analysis we used Student’s t test and 
Spearman’s rank test, using IBM SPSS 20. The thresh-
old of significance was p <0.05.
RESuLTS
Our investigation included 53. patients undergoing dial-
ysis. The average age was 56.47±11.79 years and average 
time on dialysis 5.33±4.48 years. General patients data 
are shown in Table 1.
34
According to the monitoring of patients in the two-
year period, patients were divided into two groups: 
alive  group (41 patients) and  deceased group (12 
patients).  In our study total biannual mortality was 
22.64%.
In group of deceased patients biannual mortality was 
30% in patients with CKD and DM, 16.5% in patients 
with hypertensive nephroangiosclerosis, 37.5% IN CKD 
caused with polycystic kidney disease and 75% in en-
demic nephropathy CKD.
The patients with poor outcome had significantly lower 
hemoglobin(Hgb) levels, lower levels of albumin and 
higher brain natriuretic peptide(p<0.05). Furthermore, 
deceased patients had lower levels of total CHOL and 
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Patients data(total) Xsr±SD 
Number(N) 53 
Age(Years) 56.47±11.79 
Time on dialysis(years) 5.33±4.48 
BMI(kg/m²)* 23.53±3.65 
KT/Vsp indeks** 1.12±0.15 
Outcome 
Variables Alive (41 patients) Xsr±SD 
Deceased (12 patients) 
Xsr±SD p 
Gender(M/F) 20/21 5/7 0.664 
Age(Years) 55.44±11.12 60.00±14.27 0.247 
Time on dialy-
sis(years) 5.45±4.81 4.91±3.50 0.716 
BMI(kg/m²)* 23.67±4.12 23.04±1.48 0.604 
KT/Vsp index 1,13±0.16 1.10±0.10 0.603 
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Figure 1.
The distribution of patients according to the LVMi
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Table 2.  
Basic patients parameters based on outcome during the two-year follow-up 
Outcome 
Variables Alive (41 patients) Xsr±SD 
Deceased (12 patients) 
Xsr±SD p 
Hgb(g/l) 104.50±14.12 94.50±15.46 0.040 
Hematocrit (%) 0.33±0.04 0.30±0.04 0.031 
MCV 91.79±6.37 86.9±8.13 0.035 
Alb(g/l) 38.23±2.79 35.53±3.07 0.006 
hsCRP(mg/l) 13.39±46.12 13.08±16.68 0.982 
Hcy(µmol/l) 30.77±10.90 25.68±12.36 0.173 
Total CHOL(mmol/l) 4.28±1.01 3.97±0.92 0.344 
Trig (mmol/l) 1.40±0.59 1.51±0.64 0.576 
LDL(mmol/l) 2.67±0.83 2.39±0.89 0.313 
NT proBNP(pmol/l) 1274.41±1237.71 2200.97±1799.95 0.046 
Feritin(µG/L) 74.60±69.18 100.85±100.22 0.303 
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Elevated PTH levels in serum was present in 42 (79.24%) 
patients. LVH had the 43 (81.13%) patients. Of them 18 
(33.96%) patients had concentric LVH and 25 (47.16%) 
had eccentric LVH. Dilation of the left ventricle had 4 
(7.54%) patients, while 6 (11:32%) had normal left ven-
tricle. Disorder of systolic disfunction (FSLK <25%) had 
5 (9.43%) patients. Th distribution of patients according 
to the LVMi values is shown in Fig. 1.
Between the serum concentration of PTH and IVSd, 
LVPWd exists positive correlation (p <0.01). Between 
concentrations of serum PTH and LVMi there is a posi-
tive correlation (p <0.05). Between PTH levels and other 
echocardiographic parameters for the assessment of 
hypertrophy, dilatation and systolic function of the left 
ventricule there is no correlation (p >0.05).(Figure 2.)
(Table 3.)
Figure 2.
The correlation between PTH and LVMi values
14
E. Muzurovič, S. Vujošević, M. Ratković, D. Radunović, D. Božović. The impact of secondary hyperparathyroidism on 
echocardiographic parameters in hemodialysis patients. Acta Med Croatica, Vol. 70 (2016) (Suppl. 2) 32-40
36
Table 3.
The relationship between PTH and echocardiographic parameters for the assessment of hypertrophy, dilatation and 
systolic function of the left ventricle
Alive patients had lower PTH and lower values of  Phos 
levels in relation to the deceased. The Phos levels are 
significantly lower in alive patients against the deceased 
patients (p<0.05). Considering echocardiographic pa-
rameters, patients with poor outcome had significantly 
higher LVMi, lower LVEF and FSLV, less IVSd and 
PWLVd(p<0.05) (Table 4).
DISCuSSION
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Table 3.  
The relationship between PTH and echocardiographic parameters for the as-
sessment of hypertrophy, dilatation and systolic function of the left ventricle 
 
Test parameters Xsr±Sd Značajnost - p 
LAd (mm)** 41.67±5.67  
ρemp=0.287 
p=0.037 < 0.05 PTH (pmol/l) 43.44±41.86 
EDDLV (mm)*** 55.24±6.47  
ρemp=0.281 
p=0.041 < 0.05 PTH (pmol/l) 43.44±41.86 
ESDLV (mm)**** 37.11±5.86  ρemp=0.164 
p=0.241 > 0.05 PTH (pmol/l) 43.44±41.86 
IVSd (mm) 11.90±1.62  
ρemp=0.389 
p=0.004 < 0.01 PTH (pmol/l) 43.44±41.86 
PWLVd (mm) 11.60±1.56  
ρemp=0.378 
p=0.005 < 0.01 PTH (pmol/l) 43.44±41.86 
RV (d/mm)***** 24.60±3.91  
ρemp=0.430 
p=0.001 < 0.01 PTH (pmol/l) 43.44±41.86 
LVMi (g/m2) 151.79±41.82  
ρemp=0.315 
p=0.022 < 0.05 PTH (pmol/l) 43.44±41.86 
iEDVLV (ml/m2) 101.49±32.32  ρemp=0.172 
p=0.218 > 0.05 PTH (pmol/l) 43.44±41.86 
FSLV (%) 33.03±6.34  ρemp=0.008 
p=0.952 > 0.05 PTH (pmol/l) 43.44±41.86 
LVEF (%) 64.54±8.20  ρemp=--0.026 
p=0.851 > 0.05 PTH (pmol/l) 43.44±41.86 
 
**left atrium diameter, ***left vetricular end-dyastolic diameter, **** left vetricular end-sistolic diameter, 
*****right ventricular diameter 
 
 
ditional risk factors for CVD(15,16). Non-traditional risk 
factors are consequences of uremic environment and can 
be connected also with the type of dialysis. These risk 
factors cause LVH and accelerate atherosclerosis, and 
that results in increased cardiovascular morbidity and 
mortality in patients on HD. The monitoring of risk fac-
tors for CVD, can significantly improve cardiovascular 
outcome in patients treated with HD.
Hemodialysis patients are often accompanied by SHPT, 
which consists of three components: hypocalcemia, hy-
perphosphatemia and calcitriol deficiency.
** left atrium diameter, *** left vetricular end-dyastolic diameter,
**** left vetricular end-sistolic diameter, ***** right ventricular diameter
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This association plays an important role in causing car-
diovascular disease, arterial calcification, disorders of 
the immune system, neurobehavioral changes and in-
adequate erythropoiesis(17). Arterial calcification lead 
to an increase in afterload and consecutive result in re-
modeling of cardiac muscle in the direction of LVH.  In 
patients with CKD phosphate is regarded as a ‘uremic 
toxin’. Statistical association between serum phosphate 
and all-cause mortality in patients on dialysis has trans-
formed the phosphate molecule from a subject of little 
interest 10 years ago to the ‘dialysis enemy number 1’ 
today(18). until recently, PTH and vitamin D were the 
only recognized regulators of phosphate metabolism. 
In the last decade, several novel regulators of mineral 
homeostasis have been discovered: phosphate regulating 
gene, fibroblast growth factor 23 (FGF23), and the fam-
ily of stanniocalcins (STC1 and STC2)(19). Even with the 
increasing knowledge on phosphate metabolism and its 
role in renal failure patients, interventional measures are 
still limited.  PTH has a permissive role for fibroblast 
activation and myocardial fibrosis. Thus, it has been ob-
served that elevated PTH levels in ESRD cause irrevers-
ible interstitial fibrosis with collagen deposition(20).
The fact that progression of LVH was strongly linked 
to subsequent mortality and cardiovascular events inde-
pendently of baseline LVMi and of a large series of tradi-
tional and emerging risk factors is of relevance because 
it indicates that assessing changes in LVMI is at least 
as important as estimating LVMI. Like in the study by
Foley et al(21), we found that LVH worsens with time. 
CVD is the most common cause of morbidity and mor-
tality in patients on chronic HD. During the follow-up 
period, in our study, biannual mortality was 22.64%. 
Cardiovascular mortality in CKD patients is approxi-
 
 
Table 4.  
Echocardiographic parameters and calcium disorders parameters based on 
outcome during the two-year follow-up 
 
Outcome 
Variables Alive (41 patients) Xsr±SD 
Deceased (12 patients) 
Xsr±SD p 
PTH(pmol/l) 39.56±39.83 56.69±47.62 0.216 
Ca(mmol/l) 2.31±0.31 2.33±0.23 0.0887 
Phos(mmol/l) 1.72±0.39 2.07±0.49 0.025 
Alk P(mmol/l) 81.59±68.68 90.58±99.39 0.721 
LVMi(g/m2) 145.56±39.06 173.08±45.60 0.044 
iEDVLV(ml/m2) 99.09±30.52 109.71±38.17 0.322 
IVSd(mm) 11.51±1.59 12.58±1.31 0.039 
PWLVd(mm) 11.36±1.59 12.41±1.64 0.039 
LVEF(%) 66.05±7.68 60.61±5.72 0.028 




Variables Alive (41 patients) Xsr±SD 
Deceased (12 patients) 
Xsr±SD p 
PTH(pmol/l) 39.56±39.83 56.69±47.62 0.216 
Ca(mmol/l) 2.31±0.31 2.33±0.23 0.0887 
Phos(mmol/l) 1.72±0.39 2.07±0.49 0.025 
Alk P(mmol/l) 81.59±68.68 90.58±99.39 0.721 
LVMi(g/m2) 145.56±39.06 173.08±45.60 0.044 
iEDVLV(ml/m2) 99.09±30.52 109.71±38.17 0.322 
IVSd(mm) 11.51±1.59 12.58±1.31 0.039 
PWLVd(mm) 11.36±1.59 12.41±1.64 0.039 
LVEF(%) 66.05±7.68 60.61±5.72 0.028 









mately 9% annually(22,23).  Our results are similar to the 
results of Sameiro-Faria and associated. In their study, 
during the follow-up period, 18.5% died(24).
In our study, the prevalence of SHPT was 79.24%, while 
the prevalence of SHPT in the works of Owda and as-
sociates was 79%(17). 
The prevalence of LVH in HD is high. In our study LVH 
had the 43 (81.13%) patients. Of them 18 (33.96%) pa-
tients had concentric LVH and 25 (47.16%) had eccentric 
LVH.  Compared to our results, the Canadian Prospec-
tive Cohort Study 25, which followed 433 patients with 
terminal renal disease, 74% of patients had LVH, 35% 
had left ventricular dilatation, while 15% had systolic 
dysfunction. In the group of patients LVH, 44% had 
concentric, while 30% of patients had eccentric hyper-
trophy of the left chamber. Results of echocardiographic 
parameters of our patients were consistent with the re-
sults of Foley and associates, who followed 227. patients. 
In their study were given the following values of  ultra-
sonography parameters: LVMi 161 (g/m2), iEDVLv 88 
ml/m2 and FSLv 34%(21). In our study, those parameters 
are equaled LVMi 151.79 (g/m2), iEDVLv 101.49 mL/m2 
and FSLV 33.03%.
Concentric hypertrophy of left ventricular diasto-
lic function disturbs the heart. As a consequence HD 
patients can have pulmonary edema and development 
of hypotension during hemodialysis(26-28). Diastolic 
dysfunction occurs in 50-60% of patients treated with 
regular HD. When you increase the stiffness of the LV 
and LV load volume, significantly increase the pressure 
in it. A small increase of volume can be accompanied 
by the development of pulmonary capillary congestion 
and the development of pulmonary edema(29). In HD pa-
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tients the risk of de novo development of ischemic heart 
disease is significantly higher if the LVMi >160 g/m2, 
relative to LVMi <150 g/m2. Concentric LV hypertrop-
hy, LV dilatation and impaired systolic function are 
independent risk factors for de novo development of 
ischemic heart disease(30). Increase LVMi for more than 
1 g/m2 per month increases the risk of developing car-
diovascular complications(25). In patients with normal 
volume and normal LV systolic function, high index of 
left ventricle (LVMi >120 g/m2) and the relationship of 
weight/volume of left ventricle >2.2 g/ml, are indepen-
dently associated with late mortality (after 2 years star-
ting hemodialysis). In patients with LV dilatation and 
normal LV systolic dysfunction, the increased volume 
of the left LV (iEDVLV >120 mL/min) and LVMi/iEDV 
<1.8 mL see, are also associated with an increased risk 
of late mortality(31).
In our work, between total serum PTH and LVMi, IVSd, 
PWLVd  there is a statistically significant correlation. 
This leads to the conclusion that patients with higher 
values  of PTH have a more pronounced LVH, as com-
pared to those with normal or subnormal levels of PTH. 
Secondary hyperparathyroidism is associated with LVH 
and impaired heart function(32,33).  Patients on HD also fo-
llows increased concentration of phosphate. Increased se-
rum phosphate levels >2.10 mmol/l, increased solubility 
equilibrium >5.65 mmol/l and increased PTH >500 pg/ml 
significantly increase the risk of mortality in patients tre-
ated with regular HD(33,34). Reduced aortic velum opening 
leads to the development of concentric LV hypertrophy. 
The mass of the left ventricule may be increased due to a si-
gnificant increase of myocardial fibrosis of interstitium (fi-
broblast proliferation, increased production and deposition 
of extracellular matrix proteins in intersticium infarction). 
In dialysis patients, increased concentration of PTH leads 
to the development of myocardial fibrosis of interstitium(16).
The reduction of PTH levels to normal ranges may have 
beneficial effect to reduce left ventricular hypertrophy and 
improve heart function. Thus, among hemodialysis popu-
lation, higher parathyroid hormone concentrations were 
associated with higher all-cause mortality risk, mostly 
explained by fatal cardiovascular events(35-39).
 Restricted phosphate intake, non-calcium based phosphate 
binders, new vitamin D metabolites and calcimimetics con-
tribute to better control of secondary hyperparathyroidism, 
prevent coronary calcification and decrease the morbidity 
and mortality rate in patients on regular HD(40,41).
CONCLuSION
In conclusion, SHPT, hyperphosphatemia and high Ca×P 
product are risk factors for adverse outcome in patients on 
HD. Regular monitoring and maintaining of PTH, serum 
calcium, phosphorus and Ca×P  product within the target 
range contribute to lowering the cardiovascular morbidi-
ty and mortality and improving the quality of life of HD 
patients. Patients on HD have high risk for cardiovascular 
morbidity and mortality. Echocardiographic assessment 
for cardiovascular status in patients on HD identifies those 
with increased risk of cardiovascular complications, LVH, 
congestive heart failure, and heart valve calcification. 
Establishing the most sensitive parameters for identi-
fying patients at risk for cardiovascular complications 
enables successfull treatment.
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SAŽETAK 
uTJECAJ SEKuNDARNOG HIPERPARATIREOIDIZMA NA EHOKARDIO-
GRAFSKE POKAZATELJE u HEMODIJALIZIRANIH BOLESNIKA
E. MuZuROVIć, S. VuJOšEVIć, M. RATKOVIć1, D. RADuNOVIć1 i D. BOŽOVIć2
Klinički centar Crne Gore, Interna klinika, Odjel za endokrinologiju,
1Klinika za urologiju i nefrologiju, Odjel za nefrologiju i 
2Centar za laboratorijsku dijagnostiku, Podgorica, Crna Gora
Srčanožilne (SŽ) bolesti su vodeći uzrok smrtnosti u bolesnika na hemodijalizi. Bolesnici su izloženi brojnim 
čimbenicima rizika za SŽ komplikacije, koje su u prvom redu posljedica uremije i dijalize. Cilj našeg prospek-
tivnog istraživanja jest ispitati učestalost sekundarnog hiperparatireoidizma i hipertrofije lijeve klijetke, i njiho-
vu međuigru kao predskazatelja smrtnosti u bolesnika na hemodijalizi. Istraživanje je uključilo 53 bolesnika. 
Svim bolesnicima su mjereni ehokardiografski parametri za procjenu hipertrofije lijeve klijetke i laboratorijski 
parametri koštanog  metabolizma. Pratila se smrtnost bolesnika tijekom dvije godine.  Povišena razina PTH 
u serumu bila je prisutna u 79,24% bolesnika, hipertrofiju lijeve klijetke imalo je 81,13% bolesnika. Preživjeli 
su imali niže vrijednosti PTH i serumskog fosfora (p <0,05)  u odnosu na preminule bolesnike. Analizirajući 
ehokardiografske parametre, bolesnici s lošim ishodom imali su značajno viši indeks mase lijeve klijetke, 
niže frakcije izbacivanja i frakcijskog skraćivanja lijeve klijetke, veće promjere interventrikularnog septuma  i 
stražnje stijenke lijeve klijetke (P <0,05).  Hipertrofija lijeve klijetke je rani SŽ poremećaj koji se razvija brzo 
tijekom napredovanja kronične bolesti bubrega i u osnovi je  uremijske kardiomiopatije. Hipertrofija lijeve 
klijetke je jak pokazatelj smrtnosti u bolesnika u završnoj fazi kronične bubrežne bolesti.
Ključne riječi: PTH, ehokardiografski parametri, srčanožilna smrtnost, hemodijaliza
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